Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 12/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 12/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.45 |
| ▸ | PPARA | Q07869 | 3/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 8/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6544732 | 0.80 | PPARG (0.43) | ADRB1ADRB3PPARGPPARA | |
| SCHEMBL6422826 | 0.76 | PPARA (0.53) | PPARGPPARA | |
| SCHEMBL6364312 | 0.75 | PPARG (0.58) | PPARGPPARA | |
| SCHEMBL6544739 | 0.74 | PPARA (0.48) | PPARGPPARA | |
| SCHEMBL6545236 | 0.72 | PPARA (0.48) | ADRB1ADRB3PPARGPPARAADRB2 | |
| SCHEMBL6364104 | 0.72 | PPARA (0.52) | PPARGPPARACYP2D6 | |
| SCHEMBL6544746 | 0.70 | PPARG (0.43) | PPARGPPARA | |
| SCHEMBL6358041 | 0.68 | PPARA (0.53) | PPARGPPARACYP2D6KCNH2 | |
| SCHEMBL6545718 | 0.66 | PPARG (0.46) | PPARGPPARACYP2D6 | |
| SCHEMBL6363309 | 0.66 | PPARA (0.61) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372632-A1 | PROLIFERATIVE ACTIVATOR RECEPTOR (PPAR) COMPOUNDS | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002064130-A1 | PROLIFERATIVE ACTIVATOR RECEPTOR (PPAR) COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-08-22 | — | — | WO | disclosed |